Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 08PARIS2285, FRANCE'S PHARMACEUTICAL INDUSTRY SAYS BIOTECH, GENERICS KEY

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #08PARIS2285.
Reference ID Created Released Classification Origin
08PARIS2285 2008-12-18 09:28 2011-08-24 00:00 UNCLASSIFIED//FOR OFFICIAL USE ONLY Embassy Paris
VZCZCXRO9390
RR RUEHAG RUEHDF RUEHIK RUEHLZ RUEHROV RUEHSR
DE RUEHFR #2285/01 3530928
ZNR UUUUU ZZH
R 180928Z DEC 08
FM AMEMBASSY PARIS
TO RUEHC/SECSTATE WASHDC 5078
INFO RUCPDOC/USDOC WASHINGTON DC
RUCNMEM/EU MEMBER STATES COLLECTIVE
RUEHGV/USMISSION GENEVA 2974
RHEHAAA/WHITE HOUSE WASHINGTON DC
UNCLAS SECTION 01 OF 02 PARIS 002285 
 
SENSITIVE 
SIPDIS 
 
E.O. 12958: N/A 
TAGS: ECON ETRD FR
SUBJECT: FRANCE'S PHARMACEUTICAL INDUSTRY SAYS BIOTECH, GENERICS KEY 
TO COMPETITIVENESS 
 
NOT FOR INTERNET DISTRIBUTION 
 
1. (U) Summary:  Lack of innovation, due in part to pricing and 
information controls, has caused the French pharmaceutical industry, 
once a world leader, to fall behind its competitors.  The French 
government has taken steps to support the industry, rewarding 
innovators and promoting research and development through tax 
incentives.  But the French pharmaceutical industry wants to 
convince the GOF that France can become a major center of 
biotechnological research and development, and the EU's leading 
generics producer. The pharmaceutical industry association LEEM, 
which includes U.S. companies, told us recently that U.S. firms 
willing to invest in biotechnology in France would be welcomed with 
open arms.  End summary. 
 
FRENCH PHARMACEUTICALS INDUSTRY: A SNAPSHOT 
------------------------------------------- 
2.  (U) Historically one of Europe's premier prescription drug 
producers, the French pharmaceutical industry has witnessed slowing 
growth, down to 3% in 2007 from double-digit growth rates in the 
1990s.  Following the removal of 400 products from the GOF's 
reimbursable medicines list in an effort to cut healthcare spending, 
sales of reimbursable medicines fell for the first time in a decade. 
 With one of the highest per capita consumption rates of medicines 
in the world, France has also sought to reduce pharmaceuticals 
expenditures by curbing prescription drug use, which in the recent 
past has accounted for 20 percent of healthcare spending. 
 
3.  (SBU)  Claude Bouge, Economic Affairs Director of the French 
Pharmaceuticals  Association LEEM, told us that although the current 
pharmaceuticals market is "not magnificent," experiencing slowing 
sales and a loss of attractiveness, the health sector is high 
value-added and remains one of France's major assets.  He warned, 
however, that unless the government acts quickly on a number of 
measures to bolster the pharmaceuticals industry, the sector could 
witness a significant decline in the years to come.   Bouge noted 
the growing number of layoffs of sales representatives (Pfizer 
recently let go 500 employees in France out of a total of 3,000 
staff) as evidence of current big pharma challenges.  Bouge welcomed 
President Sarkozy's move to increase tax incentives in favor of 
research and development (see para 4), but cautioned that the French 
Government needed to go further, or watch its six-billion euro trade 
surplus plunge to what trend lines indicate could become a 
five-billion euro trade deficit within the next five years. 
 
 
EFFORTS TO INCREASE INNOVATION, IMPROVE R&D IN FRENCH 
PHARMACEUTICALS 
--------------------------------------------- -------- 
4.  (SBU) While general drug consumption remains high, regulations 
in the pharmaceuticals industry, such as a complex and unpredictable 
tax system that punishes growth and, potentially, innovative 
companies, have delayed the introduction of more innovative 
medicines.  Following the lead of the EU, former Prime Minister 
Jean-Pierre Raffarin and industry leaders initiated a Strategic 
Council for Health Industries (Conseil Stratgique des Industries de 
Sant - CSIS) in 2004 to promote France's attractiveness, 
particularly in the biotech sector, through an annual meeting of all 
health stakeholders, both public and private.  These meetings have 
succeeded in speeding up the process of introducing pharmaceutical 
products on the French market.  The CSIS has also played a role in 
influencing the GOF to introduce, and increase, tax incentives in 
favor of research and development.    Industry associations, such as 
AGIPHARM (Association des Groupes Internationaux pour la Pharmacie 
de Recherche), an association of North American pharmaceutical 
companies established in France, are also advocating for increased 
research and development budgets, and a policy environment more 
favorable to innovation. 
 
5.  (U) The GOF's tax incentives to promote research and development 
are at the heart of the current policy to improve France's 
competitiveness.  The research tax credit ("Credit impot-recherche") 
has been multiplied by 1.6 between 2007 and 2008, bringing the total 
cost of the scheme to some 3.3 billion euros in 2008, according to 
Ministry of the Economy forecasts.  Large companies of more than 
10,000 employees will receive some 39 percent of that sum. 
 
RESTORING THE COMPETITIVENSS OF FRANCE'S PHARMACEUTICALS MARKET 
---------------------------------------- 
6.  (SBU) In addition to the research tax credit and creation of the 
CSIS, the French government has accelerated market authorization for 
medicines, from most to least innovative, and taken steps to expand 
the generics market in an effort to boost industry competitiveness. 
However, LEEM's Economic Affairs Director Bouge says that if France 
is to remain competitive, the government must improve the innovation 
environment for the biotech sector.  (American biotech firms would 
"receive the red carpet treatment" were they to invest in France, he 
said.) 
 
PARIS 00002285  002 OF 002 
 
 
On generics, Bouge said that although only one in five reimbursable 
drugs in France is generic, compared to 60% and 70% in Germany and 
the UK respectively, the GOF has been pursuing an aggressive 
generics policy that has produced results in a short period of time. 
 
 
Comment 
------- 
7.  (SBU) Despite complaints on tax policy, our conversations 
indicate the pharmaceutical industry does not/not believe the GOF 
intends to balance its health care books on the back of 
pharmaceutical companies.  The industry rep with whom we met spoke 
convincingly of a government that understands that a thriving pharma 
sector is important to the country's long-term interests.  Given 
ongoing budgetary pressures though, we can expect continued 
differences between industry (including U.S. pharmaceutical 
companies) and the GOF over the valuation of innovation as captured 
in GOF reimbursable medicines policy. 
 
STAPLETON